Latest on COVID-19

  • Home
  • Latest on COVID-19

Indonesian Covid deaths add to questions over Sinovac vaccine

As we all remember, on the basis of available evidence, WHO recommended Sinovac vaccine for use in adults 18 years and older, in a two-dose schedule with a spacing of two to four weeks. There is insufficient data though on the use of Sinovac vaccine for people older than 60 years old and that it’s Phase 3 clinical data has not been published in peer reviewed medical journal.

 
Vaccine efficacy results showed that the vaccine prevented symptomatic disease in 51% of those vaccinated and prevented severe COVID-19 and hospitalization in 100% of the studied population.
 
The Sinovac-CoronaVac product is an inactivated vaccine. Its easy storage requirements make it very manageable and particularly suitable for low-resource settings. 
 
How about Sinovac safety?  The Chinese Nationla Heath Commission announced that more than 100 Million doses of its domestic vaccines had been administered in China, but it did not report any death or serious side effects. At the same time however. Covid outbreak intensifies in countries using Sinovac vaccines. 
Why?
 
The Strange Sinovac Vaccine Phenomenon, Countries Report Increased Cases After Using Vaccine

 

Read more: https://www.theepochtimes.com/the-strange-sinovac-vaccine-phenomenon-countries-report-increased-cases-after-using-vaccine_3760753.html